> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lannett Incorporating FDA Biosimilar Insulin Product Feedback
- URL: https://www.fdaweb.com/lannett-incorporating-fda-biosimilar-insulin-product-feedback/
- Published: 2021-03-10T12:00:00.000Z
- Updated: 2026-09-14T16:50:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148850

Lannett says it is incorporating feedback recently received from FDA into the design of a pivotal trial, including the type and size of the trial and primary and secondary endpoints, for biosimilar insulin glargine that Lannett is developing with partners within the HEC Group. The company [says](https://lannett.investorroom.com/2021-03-10-Lannett-Development-Of-Biosimilar-Insulin-Glargine-Product-Continues-To-Advance?ref=fdaweb.com) it sought and received comments from FDA related to the trial protocol and statistical analysis plan for the development program.